



Systemic Therapies in Melanoma

Guest Editors:

Dr. Alexandre Moulin

Jules-Gonin Eye Hospital,
Fondation Asile des Aveugles,
University of Lausanne,
Lausanne, Switzerland

Prof. Olivier Michielin

Oncology Department, Lausanne
University Hospital (CHUV),
Lausanne, Switzerland

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editors

Dear Colleagues,

In the last few years, the appraisal of the genetic background of melanoma has allowed us to identify key driver genes with oncogenic mutations and develop targeted therapies for advanced melanomas. The significant rate of response of the high mutation burden identified in skin melanomas to immunotherapy and combined therapy with checkpoint inhibitors has recently led to an impressive improvement in the 5-year overall survival in advanced skin melanoma patients. These changes, however, were not observed in metastatic uveal melanomas. This Special Issue aims to present articles assessing recent advances in systemic therapy for advanced skin and other melanomas.

Dr. Alexandre Moulin
Prof. Olivier Michielin
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)